Records containing: Recurrent WHO Grade III Glioma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-03-13A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
-
CLINICAL_TRIALS study record update · 2026-03-11Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
-
CLINICAL_TRIALS study record update · 2025-12-17A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
-
CLINICAL_TRIALS study record update · 2025-10-06A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma
-
CLINICAL_TRIALS study record update · 2025-01-10Metabolic Imaging of Patients With Lower Grade Glioma Using Hyperpolarized 13C Pyruvate
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2024-12-16Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
-
CLINICAL_TRIALS study record update · 2024-10-30Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma
-
CLINICAL_TRIALS study record update · 2024-04-29A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas